Febustad 80

Febustad 80 contains febuxostat which has effect of blocking uric acid production, decrease serum concentrations of uric acid. Febustad 80 is indicated in treatment for gout.

Pack size Box of 30 tablets, 60 tablets, 90 tablets
Shelf-life 24 months
Composition Febuxostat
Dosage forms and strengths Film-coated tablet: 80 mg
Product code :



Indicated for the chronic management of hyperuricemia in patients where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis). Febuxostat is not recommended for the treatment of asymptomatic hyperuricemia.


  • The recommended initial dosage of febuxostat for the management of hyperuricemia in patients with gout is 40 mg once daily.
    The dosage of febuxostat may be increased to 80 mg once daily in patients who do not achieve serum urate concentrations of less than 6 mg/dL following 2 weeks of therapy with febuxostat 40 mg once daily. If serum uric acid is > 6 mg/dL after 2 – 4 weeks, febuxostat 120 mg once daily may be considered.
  • Gout flare prophylaxis of at least 6 months is recommended.
  • The efficacy and safety have not been fully evaluated in patients with severe renal impairment.
  • Dosage adjustment is not needed in patients with mild to moderate renal impairment or mild hepatic impairment.
  • Pediatric: Safety and efficacy of febuxostat have not been established in pediatric patients younger than 18 years of age.
  • Geriatric: Dosage adjustment based on age is not needed.


Febustad 80 is administered orally without regard to meals or antacids.

  • Known hypersensitivity to any ingredient in the formulation.
  • Concomitant therapy with azathioprine, mercaptopurine, or theophylline.


  • Gout flares;
  • Headache;
  • Diarrhoea,
  • Nausea;
  • Liver function abnormalities;
  • Rash;
  • Oedema.

Cardio-vascular disorders
Treatment of chronic hyperuricaemia
Treatment with febuxostat in patients with pre-existing major cardiovascular diseases (e.g. myocardial infarction, stroke or unstable angina) should be avoided, unless no other therapy options are appropriate.

Medicinal product allergy/hypersensitivity
Rare reports of serious allergic/hypersensitivity reactions, including life-threatening Stevens-Johnson Syndrome, Toxic epidermal necrolysis and acute anaphylactic reaction/shock, have been collected in the post-marketing experience. In most cases, these reactions occurred during the first month of therapy with febuxostat. Some, but not all of these patients reported renal impairment and/or previous hypersensitivity to allopurinol. Severe hypersensitivity reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) were associated with fever, haematological, renal or hepatic involvement in some cases.
Patients should be advised of the signs and symptoms and monitored closely for symptoms of allergic/hypersensitivity reactions. Febuxostat treatment should be immediately stopped if serious allergic/hypersensitivity reactions, including Stevens-Johnson Syndrome, occur since early withdrawal is associated with a better prognosis. If patient has developed allergic/hypersensitivity reactions including Stevens-Johnson Syndrome and acute anaphylactic reaction/shock, febuxostat must not be re-started in this patient at any time.

Acute gouty attacks (gout flare)
Febuxostat treatment should not be started until an acute attack of gout has completely subsided. Gout flares may occur during initiation of treatment due to changing serum uric acid levels resulting in mobilization of urate from tissue deposits. At treatment initiation with febuxostat flare prophylaxis for at least 6 months with an NSAID or colchicine is recommended.
If a gout flare occurs during febuxostat treatment, it should not be discontinued. The gout flare should be managed concurrently as appropriate for the individual patient. Continuous treatment with febuxostat decreases frequency and intensity of gout flares.

Xanthine deposition
In patients in whom the rate of urate formation is greatly increased (e.g. malignant disease and its treatment, Lesch-Nyhan syndrome) the absolute concentration of xanthine in urine, could in rare cases, rise sufficiently to allow deposition in the urinary tract. As there has been no experience with febuxostat, its use in patients with Lesch-Nyhan Syndrome is not recommended.

Febuxostat use is not recommended in patients concomitantly treated with mercaptopurine/azathioprine as inhibition of xanthine oxidase (XO) by febuxostat may cause increased plasma concentrations of mercaptopurine/azathioprine that could result in severe toxicity.
No interaction studies have been performed in humans.
Where the combination cannot be avoided, a reduction of the dose of mercaptopurine/azathioprine is recommended. Based on modelling and simulation analysis of data from a pre-clinical study in rats, when coadministered with febuxostat, the dose of mercaptopurine/azathioprine should be reduced to the 20% or less of the previously prescribed dose in order to avoid possible haematological effects.
The patients should be closely monitored and the dose of mercaptopurine/azathioprine should be subsequently adjusted based on the evaluation of the therapeutic response and the onset of eventual toxic effects.

Organ transplant recipients
As there has been no experience in organ transplant recipients, the use of febuxostat in such patients is not recommended.

Co-administration of febuxostat 80 mg and theophylline 400 mg single dose in healthy subjects showed absence of any pharmacokinetic interaction. Febuxostat 80 mg can be used in patients concomitantly treated with theophylline without risk of increasing theophylline plasma levels. No data is available for febuxostat 120 mg.

Liver disorders
During the combined phase 3 clinical studies, mild liver function test abnormalities were observed in patients treated with febuxostat (5.0%). Liver function test is recommended prior to the initiation of therapy with febuxostat and periodically thereafter based on clinical judgment.

Thyroid disorders
Increased TSH values (> 5.5 μIU/mL) were observed in patients on long-term treatment with febuxostat (5.5%) in the long term open label extension studies. Caution is required when febuxostat is used in patients with alteration of thyroid function.

Febustad 80 contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not use this medicine.

There are no adequate and well controlled studies in pregnant women. Febuxostat should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when febuxostat is administered to a nursing woman.

Somnolence, dizziness, paraesthesia and blurred vision have been reported with the use of febuxostat. Patients should exercise caution before driving, using machinery or participating in dangerous activities until they are reasonably certain that febuxostat does not adversely affect performance.